PUMA BIOTECH Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PUMA BIOTECH, and what generic alternatives to PUMA BIOTECH drugs are available?
PUMA BIOTECH has one approved drug.
There are ten US patents protecting PUMA BIOTECH drugs.
There are one hundred and seventy-one patent family members on PUMA BIOTECH drugs in thirty-five countries and eight supplementary protection certificates in eight countries.
Drugs and US Patents for PUMA BIOTECH
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,399,865 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,982,043 | ⤷ Sign Up | ⤷ Sign Up | ||||
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 8,669,273 | ⤷ Sign Up | ⤷ Sign Up | ||||
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PUMA BIOTECH
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | 6,288,082 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PUMA BIOTECH Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Croatia | P20192026 | ⤷ Sign Up |
South Korea | 20220143154 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2011055303 | ⤷ Sign Up |
Slovenia | 2498756 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PUMA BIOTECH Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3000467 | 301237 | Netherlands | ⤷ Sign Up | PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180904 |
3000467 | 26/2023 | Austria | ⤷ Sign Up | PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 (MITTEILUNG) 20180904 |
3000467 | 2390021-0 | Sweden | ⤷ Sign Up | PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180904 |
3000467 | 2023C/527 | Belgium | ⤷ Sign Up | PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.